Skip to main content
. 2015 Sep 21;5:14257. doi: 10.1038/srep14257

Figure 3. Pharmacological activation of TRPV4 decreases TEC proliferation via modulation of ERK1/2 but not AKT pathway.

Figure 3

(A) Representative Western blots showing ERK1/2 phosphorylation in control and GSK treated NEC and TEC. (B) Densitometric analysis of the Western blots showing a decrease in ERK1/2 phosphorylation in TEC treated with GSK (100 nM). ERK1/2 phosphorylation was measured by normalizing phospho-ERK1/2 to total-ERK1/2 and was expressed as a fold change relative to NEC. (C) Representative Western blots depicting ERK1/2 phosphorylation TEC transfected with TRPV4-EGFP. (D) Densitometric analysis of the Western blots for ERK1/2 phosphorylation. ERK1/2 phosphorylation was measured by normalizing phospho-ERK1/2 to total-ERK1/2 and was expressed as a fold change relative to TEC. All the data shown is mean ± SEM from at least three independent experiments.